BioVersys AG / Key word(s): Conference BIOVERSYS TO PRESENT BV100 PHASE 2 DATA AT 35TH ESCMID GLOBAL 2025 08.04.2025 / 07:00 CET/CEST Basel, Switzerland. April 08, 2025, 7am CEST. Oral presentation on April 13, 2025, highlighting positive BV100 Phase 2 VABP trial read-out with excellent efficacy and safety data Complementary [ … ]

Ad hoc announcement pursuant to Art. 53 LR Basel, Switzerland. March 31, 2025, 7am CET Important patent around BioVersys’ BV100 drug candidate has been granted, protecting the proprietary rifabutin IV formulation technology in China BV100 patents have now been granted in over 25 countries, including in US, Europe, UK and China BioVersys AG (SIX [ … ]

Ad hoc announcement pursuant to Art. 53 LR Basel, Switzerland. March 26, 2025, 7am CET BV100: Positive Phase 2 VABP trial read-out with excellent safety and efficacy data Alpibectir: Phase 2a EBA trial delivered very strong proof of concept Preclinical candidates from BioVersys’ two proprietary platforms continue to progress Full Year 2024 oper [ … ]

Ad hoc announcement pursuant to Art. 53 LR Basel, Switzerland. March 19, 2025, 7am CET.  Ad hoc announcement pursuant to Art. 53 LR Under the BioVersys and GSK collaboration agreement, GSK is evaluating the early bactericidal activity (EBA) of alpibectir-ethionamide (AlpE) in a pulmonary tuberculosis (TB) trial, in combination with first-line TB  [ … ]

BioVersys AG / Key word(s): Annual Results BIOVERSYS ANNOUNCES REPORTING DATE FOR FULL-YEAR 2024 FINANCIAL RESULTS AND EVENT DETAILS 14.03.2025 / 07:00 CET/CEST Basel, Switzerland. March 14, 2025, 7am CET BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of  [ … ]

Ad hoc announcement pursuant to Art. 53 LR Basel, Switzerland. March 10, 2025, 7am CET.  Ad hoc announcement pursuant to Art. 53 LR Partial exercise of over-allotment option following end of stablization period in context of the company’s initial public offering (IPO) An additional 47,862 new shares to be issued by BioVersys BioVersys raised tot [ … ]

BioVersys AG / Key word(s): Miscellaneous BIOVERSYS SUCCESSFULLY ADVANCES BV500 NTM PROGRAM WITH CONTINUED SUPPORT FROM CF AMR SYNDICATE 11.02.2025 / 07:00 CET/CEST Basel, Switzerland. February 11, 2025, 7am CET   BV500 reaches second milestone, with the advancement of multiple broadly profiled and highly potent oral Lead c [ … ]

BioVersys AG / Key word(s): IPO BIOVERSYS SUCCESSFULLY COMPLETES ITS IPO AT CHF 36 PER SHARE AND STARTS TRADING ON THE SIX SWISS EXCHANGE TOMORROW, FEBRUARY 07, 2025 06.02.2025 / 07:00 CET/CEST __________ THIS IS A RESTRICTED COMMUNICATION AND YOU MUST NOT FORWARD IT OR ITS CONTENTS TO ANY PERSON TO WHOM FORWARDING THIS COMMU [ … ]